


Anticancer agent 110

Cat. No.:	HY-149805
CAS No.:	887349-03-3
Molecular Formula:	C ₁₈ H ₁₃ FN ₆ OS
Molecular Weight:	380.4
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis ^[1] .
In Vitro	Anticancer agent 110 (compound 3d) (0.01 μM-100 μM) inhibits leukemia K-562 cells with IC ₅₀ of 0.7 μM ^[1] . Anticancer agent 110 (70 nM, 700 nM; 24 h) causes a higher level of DNA damage in K-562 cells ^[1] . Anticancer agent 110 (70 nM, 700 nM; 24 h) induces pro-apoptotic changes in the morphology of leukemia cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pokhodylo N, et al. Bioisosteric replacement of 1H-1,2,3-triazole with 1H-tetrazole ring enhances anti-leukemic activity of (5-benzylthiazol-2-yl)benzamides. Eur J Med Chem. 2023 Mar 15;250:115126.

[2]. Pokhodylo N, et al. Bioisosteric replacement of 1H-1,2,3-triazole with 1H-tetrazole ring enhances anti-leukemic activity of (5-benzylthiazol-2-yl)benzamides. Eur J Med Chem. 2023 Mar 15;250:115126.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA